Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INVAGESIC FORTE vs CO-GESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Management of mild to moderate pain,Off-label: acute pain, dental pain, postoperative pain
FDA: Management of moderate to moderately severe pain where an opioid is appropriate.,Off-label: Not commonly used off-label; may be considered for refractory pain conditions.
One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in Cr Cl <30 m L/min)
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Codeine is metabolized via CYP2D6 to morphine, and via CYP3A4 to norcodeine. Ibuprofen is metabolized primarily via CYP2C9.
Hydrocodone: primarily hepatic via CYP3A4-mediated N-demethylation to norhydrocodone (active) and O-demethylation via CYP2D6 to hydromorphone (active). Acetaminophen: hepatic via glucuronidation and sulfation; minor oxidation by CYP2E1 to NAPQI (toxic metabolite).
Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5%
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
99% (primarily albumin; binding reduced in hypoalbuminemia, uremia, and neonates)
<20%; primarily binds to albumin.
0.1-0.2 L/kg (clinical meaning: low Vd indicates limited extravascular distribution, consistent with high protein binding and acidic drug nature)
1.2–1.9 L/kg; suggests extensive distribution into total body water.
Oral: 80-100% (food delays absorption but does not reduce extent)
Oral: 85–95%; rectal: 70–80%.
Contraindicated in severe renal impairment (e GFR < 30 m L/min/1.73 m²). For moderate impairment (e GFR 30-59 m L/min/1.73 m²): use lowest effective dose, maximum 4 tablets per day; avoid in dialysis.
GFR 30-59 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8 hours; GFR <10 m L/min: Administer every 12 hours; avoid use in severe renal impairment.
Contraindicated in Child-Pugh class C (severe hepatic impairment). For class B (moderate): reduce dose by 50% and monitor; do not exceed 4 tablets per day. Class A (mild): no adjustment but caution.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; Child-Pugh Class C: Use not recommended due to hepatotoxicity risk.
Not recommended for pediatric patients under 18 years of age due to risk of serious adverse effects.
Children ≥2 years: Hydrocodone 0.1-0.2 mg/kg/dose (max 5 mg/dose) plus acetaminophen 10-15 mg/kg/dose (max 500 mg/dose) orally every 4-6 hours as needed; maximum 5 doses per day.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours); maximum 4 tablets per day. Avoid in patients with creatinine clearance < 30 m L/min. Monitor for renal function, hepatic function, and gastrointestinal bleeding.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours) due to increased sensitivity to opioids and renal clearance decline; monitor for respiratory depression and sedation.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome; risk from concomitant use with benzodiazepines or other CNS depressants; cytochrome P450 2D6 ultra-rapid metabolizers (risk of life-threatening respiratory depression from codeine).
Risk of addiction, abuse, and misuse; serious, life-threatening or fatal respiratory depression from opioid use; accidental ingestion of acetaminophen can cause acute liver failure; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; ultra-rapid metabolism of codeine (CYP2D6); gastrointestinal bleeding (NSAIDs); cardiovascular thrombotic events; renal toxicity; hepatic impairment; elderly patients; pregnancy.
Addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risk with concomitant use of CNS depressants; severe hypotension; seizures; serotonin syndrome; adrenal insufficiency; hepatotoxicity (acetaminophen overdose); hypersensitivity reactions; constipation; urinary retention; impaired mental/physical abilities.
Hypersensitivity to codeine, ibuprofen, or any component; patients with significant respiratory depression; acute or severe bronchial asthma (in an unmonitored setting or without resuscitative equipment); gastrointestinal bleeding; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery; children <12 years old; breastfeeding (ultra-rapid metabolizers of codeine).
Hypersensitivity to hydrocodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction (e.g., paralytic ileus); use of MAO inhibitors (concurrent or within 14 days).
Avoid grapefruit juice as it may increase tramadol levels. High-fat meals may delay absorption but not overall effect. No specific dietary restrictions beyond avoiding alcohol.
Avoid grapefruit and grapefruit juice as they may alter metabolism of hydrocodone. Take with food if gastrointestinal upset occurs. Avoid alcohol-containing foods or beverages. No other significant food interactions.
Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester use associated with increased risk of miscarriage and cardiac malformations. Paracetamol component is generally considered low risk but chronic high doses may increase risk of fetal hepatotoxicity.
First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductus arteriosus and oligohydramnios.
Diclofenac excreted in breast milk in low amounts (M/P ratio ~0.02-0.05); paracetamol M/P ratio ~1.0. Both considered compatible with breastfeeding at recommended doses. However, avoid if infant has hypersensitivity or G6PD deficiency. Monitor infant for sedation or respiratory depression if used with opioids.
No data on M/P ratio; use with caution. Low molecular weight may be excreted into breast milk; monitor infant for sedation or respiratory depression.
Increased renal clearance in pregnancy may reduce plasma levels; however, dose adjustments are not recommended due to fetal safety concerns. Use lowest effective dose for shortest duration. Avoid NSAIDs after 20 weeks gestation; if necessary, reduce dose and limit duration.
No specific dose adjustments required; however, due to increased renal clearance in pregnancy, shortened dosing intervals or higher doses may be needed for adequate analgesia. Monitor clinical response and adjust accordingly.
Invagesic Forte (paracetamol 500 mg + tramadol 37.5 mg) is a fixed-dose combination analgesic. Tramadol is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy. Monitor for serotonin syndrome when used with SSRIs, SNRIs, or MAOIs. Maximum daily tramadol dose is 300 mg (8 tablets). Seizure risk increases in patients taking SSRIs, tricyclics, or with epilepsy.
Co-Gesic is a fixed-dose combination of hydrocodone and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g. Hydrocodone is a Schedule II controlled substance with abuse potential. Use with caution in patients with respiratory compromise, COPD, or sleep apnea. Avoid concurrent use with other CNS depressants including alcohol. In opioid-tolerant patients, withdrawal may occur if discontinued abruptly.
Take exactly as prescribed; do not exceed 8 tablets daily.,May cause dizziness or drowsiness; avoid driving or operating machinery.,Avoid alcohol while taking this medication.,Do not take with other medications containing acetaminophen (paracetamol) to avoid liver damage.,Report severe constipation, nausea, or difficulty breathing to your doctor.,Do not stop abruptly; withdrawal symptoms may occur.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol while taking this medication due to risk of liver damage and increased sedation.,Do not take other medications containing acetaminophen (Tylenol, many cold/flu products) to avoid exceeding the maximum daily dose (4 grams).,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of children and dispose of unused medication properly (take-back programs preferred).,Do not crush or chew extended-release formulations (if applicable).,Report signs of liver injury (yellowing skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INVAGESIC FORTE vs CO-GESIC, answered by our medical review team.
INVAGESIC FORTE is a Opioid Analgesic Combination that works by Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.. CO-GESIC is a Opioid Analgesic Combination that works by CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INVAGESIC FORTE and CO-GESIC depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INVAGESIC FORTE is: One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.. The standard adult dose of CO-GESIC is: 1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INVAGESIC FORTE and CO-GESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INVAGESIC FORTE is classified as Category C. Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester u. CO-GESIC is classified as Category C. First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.